GLPwatch
Obesity
Approved indication
Last updated 2026-05-28 15:46 UTCFDA-approved GLP-1 drugs for obesity include Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), with semaglutide specifically studied in multiple trials (e.g., STEP program) for its effects on weight loss, appetite, and energy intake in adults with obesity or overweight.
AI summary of the sources below.
How Obesity connects
- Drugs SaxendaWegovyZepbound
- Molecules LiraglutideSemaglutideTirzepatide
- Research 3,105 papers
Approved GLP-1 drugs (3)
Research (50)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Semaglutide lowers body weight in rodents via distributed neural pathways.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
- GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Common questions
- Which GLP-1 drugs are FDA-approved for Obesity?
- Saxenda, Wegovy and Zepbound are FDA-approved for obesity.
- Is there research on GLP-1 drugs for Obesity?
- GLPwatch tracks 3105 research papers on GLP-1 drugs and obesity. This research is investigational and does not imply FDA approval.